Skip to main content
Top
Published in: CNS Drugs 9/2007

01-09-2007 | Therapy In Practice

Diagnosis and Treatment of Agoraphobia with Panic Disorder

Authors: Dr Giulio Perugi, Franco Frare, Cristina Toni

Published in: CNS Drugs | Issue 9/2007

Login to get access

Abstract

Agoraphobia with panic disorder is a phobic-anxious syndrome where patients avoid situations or places in which they fear being embarrassed, or being unable to escape or get help if a panic attack occurs. During the last half-century, agoraphobia has been thought of as being closely linked to the recurring panic attack syndrome, so much so that in most cases it appears to be the typical development or complication of panic disorder.
Despite the high prevalence of agoraphobia with panic disorder in patients in primary-care settings, the condition is frequently under-recognised and undertreated by medical providers. Antidepressants have been demonstrated to be effective in preventing panic attacks, and in improving anticipatory anxiety and avoidance behaviour. These drugs are also effective in the treatment of the frequently coexisting depressive symptomatology. Among antidepressant agents, SSRIs are generally well tolerated and effective for both anxious and depressive symptomatology, and these compounds should be considered the first choice for short-, medium- and long-term pharmacological treatment of agoraphobia with panic disorder. The few comparative studies conducted to date with various SSRIs reported no significant differences in terms of efficacy; however, the SSRIs that are less liable to produce withdrawal symptoms after abrupt discontinuation should be considered the treatments of first choice for long-term prophylaxis. Venlafaxine is not sufficiently studied in the long-term treatment of panic disorder, while TCAs may be considered as a second choice of treatment when patients do not seem to respond to or tolerate SSRIs. High-potency benzodiazepines have been shown to display a rapid onset of anti-anxiety effect, having beneficial effects during the first few days of treatment, and are therefore useful options for short-term treatment; however, these drugs are not first-choice medications in the medium and long term because of the frequent development of tolerance and dependence phenomena. Cognitive-behavioural therapy is the best studied non-pharmacological approach and can be applied to many patients, depending on its availability.
Literature
1.
go back to reference Cassano GB, Petracca A, Perugi G, et al. Derealization and panic attacks: a clinical evaluation on 150 patients with panic disorder/agoraphobia. Compr Psychiatry 1989 Jan–Feb; 30(1): 5–12PubMedCrossRef Cassano GB, Petracca A, Perugi G, et al. Derealization and panic attacks: a clinical evaluation on 150 patients with panic disorder/agoraphobia. Compr Psychiatry 1989 Jan–Feb; 30(1): 5–12PubMedCrossRef
2.
go back to reference Toni C, Cassano GB, Perugi G, et al. Psychosensorial and related phenomena in panic disorder and in temporal lobe epilepsy. Compr Psychiatry 1996 Mar–Apr; 37(2): 125–33PubMedCrossRef Toni C, Cassano GB, Perugi G, et al. Psychosensorial and related phenomena in panic disorder and in temporal lobe epilepsy. Compr Psychiatry 1996 Mar–Apr; 37(2): 125–33PubMedCrossRef
3.
go back to reference Toni C, Perugi G, Frare F. A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Pharmacopsychiatry 2000 Jul; 33(4): 121–31PubMedCrossRef Toni C, Perugi G, Frare F. A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Pharmacopsychiatry 2000 Jul; 33(4): 121–31PubMedCrossRef
5.
go back to reference Hauri PJ, Friedman M, Ravaris CL. Sleep in patients with spontaneous panic attacks. Sleep 1989 Aug; 12(4): 323–37PubMed Hauri PJ, Friedman M, Ravaris CL. Sleep in patients with spontaneous panic attacks. Sleep 1989 Aug; 12(4): 323–37PubMed
6.
go back to reference Merritt-Davis O, Balon R. Nocturnal panic: biology, psychopathology, and its contribution to the expression of panic disorder. Depress Anxiety 2003; 18(4): 221–7PubMedCrossRef Merritt-Davis O, Balon R. Nocturnal panic: biology, psychopathology, and its contribution to the expression of panic disorder. Depress Anxiety 2003; 18(4): 221–7PubMedCrossRef
7.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC; American Psychiatric Association, 2000 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC; American Psychiatric Association, 2000
8.
go back to reference Benedetti A, Perugi G, Toni C. Hypochondriasis and illness phobia in panic-agoraphobic patients. Compr Psychiatry 1997 Mar–Apr; 38(2): 124–31PubMedCrossRef Benedetti A, Perugi G, Toni C. Hypochondriasis and illness phobia in panic-agoraphobic patients. Compr Psychiatry 1997 Mar–Apr; 38(2): 124–31PubMedCrossRef
9.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
10.
go back to reference First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV disorders. Research version, non-patient ed. (SCID-I/NP). New York: Biometrics Research State Psychiatric Institute, 2002 First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV disorders. Research version, non-patient ed. (SCID-I/NP). New York: Biometrics Research State Psychiatric Institute, 2002
11.
go back to reference Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(20): 22–3PubMed Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(20): 22–3PubMed
12.
go back to reference World Health Organization. Composite international diagnostic interview. V2. 0. Geneva: World Health Organization, 1997 World Health Organization. Composite international diagnostic interview. V2. 0. Geneva: World Health Organization, 1997
13.
go back to reference Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Therapy 1979; 17: 263–7CrossRef Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Therapy 1979; 17: 263–7CrossRef
14.
go back to reference Chambless DL, Caputo GC, Jasin SE, et al. The mobility inventory for agoraphobia. Behav Res Ther 1985; 23: 35–44PubMedCrossRef Chambless DL, Caputo GC, Jasin SE, et al. The mobility inventory for agoraphobia. Behav Res Ther 1985; 23: 35–44PubMedCrossRef
15.
go back to reference Eaton WW, Kessler RC, Wittchen HU, et al. Panic and panic disorder in the United States. Am J Psychiatry 1994 Mar; 151(3): 413–20PubMed Eaton WW, Kessler RC, Wittchen HU, et al. Panic and panic disorder in the United States. Am J Psychiatry 1994 Mar; 151(3): 413–20PubMed
16.
go back to reference Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994 Jan; 51(1): 8–19PubMedCrossRef Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994 Jan; 51(1): 8–19PubMedCrossRef
17.
go back to reference Sheikh JI, Leskin GA, Klein DF. Gender differences in panic disorder: findings from the National Comorbidity Survey. Am J Psychiatry 2002 Jan; 159(1): 55–8PubMedCrossRef Sheikh JI, Leskin GA, Klein DF. Gender differences in panic disorder: findings from the National Comorbidity Survey. Am J Psychiatry 2002 Jan; 159(1): 55–8PubMedCrossRef
18.
go back to reference Kessler RC, Chiu WT, Jin R, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006; 63: 415–24PubMedCrossRef Kessler RC, Chiu WT, Jin R, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006; 63: 415–24PubMedCrossRef
19.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
20.
go back to reference Tyrer P. Classification of anxiety disorders: a critique of DSM-III. J Affect Disord 1986; 11: 99–107PubMedCrossRef Tyrer P. Classification of anxiety disorders: a critique of DSM-III. J Affect Disord 1986; 11: 99–107PubMedCrossRef
21.
go back to reference Roth M. Anxiety and anxiety disorders: general overview. In Roth M, Noyes Jr R, Barrows GD, editors. Handbook of anxiety: biological, clinical and cultural perspectives. Vol. 1. Amsterdam: Elsevier Science Publishers, 1988: 1–45 Roth M. Anxiety and anxiety disorders: general overview. In Roth M, Noyes Jr R, Barrows GD, editors. Handbook of anxiety: biological, clinical and cultural perspectives. Vol. 1. Amsterdam: Elsevier Science Publishers, 1988: 1–45
22.
go back to reference Breier A, Charney DS, Heninger GR. Agoraphobia with panic attacks: development, diagnostic stability, and course of illness. Arch G Psychiatry 1986; 43: 1029–36CrossRef Breier A, Charney DS, Heninger GR. Agoraphobia with panic attacks: development, diagnostic stability, and course of illness. Arch G Psychiatry 1986; 43: 1029–36CrossRef
23.
go back to reference Noyes R. The natural history of anxiety disorders. In Roth M, Noyes Jr R, Barrows GD, editors. Handbook of anxiety: biological, clinical and cultural perspectives. Vol. 1. Amsterdam: Elsevier Science Publishers, 1988: 115–33 Noyes R. The natural history of anxiety disorders. In Roth M, Noyes Jr R, Barrows GD, editors. Handbook of anxiety: biological, clinical and cultural perspectives. Vol. 1. Amsterdam: Elsevier Science Publishers, 1988: 115–33
24.
go back to reference Fava GA, Grandi S, Canestrari R. Prodromal symptoms in panic disorder with agoraphobia. Am J Psychiatry 1988; 45(12): 1564–7 Fava GA, Grandi S, Canestrari R. Prodromal symptoms in panic disorder with agoraphobia. Am J Psychiatry 1988; 45(12): 1564–7
25.
go back to reference Perugi G, Toni C, Benedetti A, et al. Delineating a putative phobic-anxious temperament in 126 panic agoraphobic patients: toward a rapprochement of European and US views. J Affect Disord 1998; 37: 11–23CrossRef Perugi G, Toni C, Benedetti A, et al. Delineating a putative phobic-anxious temperament in 126 panic agoraphobic patients: toward a rapprochement of European and US views. J Affect Disord 1998; 37: 11–23CrossRef
26.
go back to reference Sheehan DV, Sheehan KH. The classification of phobic disorders. Int J Psychiatr Med 1982; 12: 243–66CrossRef Sheehan DV, Sheehan KH. The classification of phobic disorders. Int J Psychiatr Med 1982; 12: 243–66CrossRef
27.
go back to reference Vollrath M, Koch R, Angst J. Panic disorder and sporadic panic: symptoms, diagnosis, prevalence, and overlap with depression. The Zurich Study: IX. Eur Arch Psych Neurol Sci 1990; 239(4): 221–30CrossRef Vollrath M, Koch R, Angst J. Panic disorder and sporadic panic: symptoms, diagnosis, prevalence, and overlap with depression. The Zurich Study: IX. Eur Arch Psych Neurol Sci 1990; 239(4): 221–30CrossRef
28.
go back to reference Katon W, Vitaliano PP, Russo J, et al. Panic disorder: spectrum of severity and somatization. J Nerv Ment Disord 1987; 175: 12–9CrossRef Katon W, Vitaliano PP, Russo J, et al. Panic disorder: spectrum of severity and somatization. J Nerv Ment Disord 1987; 175: 12–9CrossRef
29.
go back to reference Klein DF, Klein HM. The nosology, genetics and theory of spontaneous panic and phobia. In: Tyrer PJ, editor. Psychopharmacology of anxiety. New York; Oxford University Press, 1989: 163–95 Klein DF, Klein HM. The nosology, genetics and theory of spontaneous panic and phobia. In: Tyrer PJ, editor. Psychopharmacology of anxiety. New York; Oxford University Press, 1989: 163–95
30.
go back to reference Weissman MM, Merikangas KR. The epidemiology of anxiety and panic disorders: an update. J Clin Psychiatry 1986; 47: 11–7PubMed Weissman MM, Merikangas KR. The epidemiology of anxiety and panic disorders: an update. J Clin Psychiatry 1986; 47: 11–7PubMed
31.
go back to reference Swoboda H, Amering M, Windhaber J, et al. The long-term course of panic disorder: an 11 year follow-up. J Anxiety Disord 2003; 17(2): 223–32PubMedCrossRef Swoboda H, Amering M, Windhaber J, et al. The long-term course of panic disorder: an 11 year follow-up. J Anxiety Disord 2003; 17(2): 223–32PubMedCrossRef
32.
go back to reference Villeponteaux VA, Lydiard RB, Laraia MT, et al. The effects of pregnancy on preexisting panic disorder. J Clin Psychiatry 1992 Jun; 53(6): 201–3PubMed Villeponteaux VA, Lydiard RB, Laraia MT, et al. The effects of pregnancy on preexisting panic disorder. J Clin Psychiatry 1992 Jun; 53(6): 201–3PubMed
33.
go back to reference Cohen LS, Sichel DA, Dimmock JA, et al. Impact of pregnancy on panic disorder: a case series. J Clin Psychiatry 1994 Jul; 55(7): 284–8PubMed Cohen LS, Sichel DA, Dimmock JA, et al. Impact of pregnancy on panic disorder: a case series. J Clin Psychiatry 1994 Jul; 55(7): 284–8PubMed
34.
go back to reference Northcott CJ, Stein MB. Panic disorder in pregnancy. J Clin Psychiatry 1994 Dec; 55(12): 539–42PubMed Northcott CJ, Stein MB. Panic disorder in pregnancy. J Clin Psychiatry 1994 Dec; 55(12): 539–42PubMed
35.
go back to reference Hertzberg T, Wahlbeck K. The impact of pregnancy and puerperium on panic disorder: a review. J Psychosom Obstet Gynaecol 1999 Jun; 20(2): 59–64PubMedCrossRef Hertzberg T, Wahlbeck K. The impact of pregnancy and puerperium on panic disorder: a review. J Psychosom Obstet Gynaecol 1999 Jun; 20(2): 59–64PubMedCrossRef
36.
go back to reference Sigmon ST, Dorhofer DM, Rohan KJ, et al. Psychophysiological, somatic, and affective changes across the menstrual cycle in women with panic disorder. J Consult Clin Psychol 2000 Jun; 68(3): 425–31PubMedCrossRef Sigmon ST, Dorhofer DM, Rohan KJ, et al. Psychophysiological, somatic, and affective changes across the menstrual cycle in women with panic disorder. J Consult Clin Psychol 2000 Jun; 68(3): 425–31PubMedCrossRef
37.
go back to reference Sigmon ST, Whitcomb-Smith SR, Rohan KJ, et al. The role of anxiety level, coping styles, and cycle phase in menstrual distress. J Anxiety Disord 2004; 18(2): 177–91PubMedCrossRef Sigmon ST, Whitcomb-Smith SR, Rohan KJ, et al. The role of anxiety level, coping styles, and cycle phase in menstrual distress. J Anxiety Disord 2004; 18(2): 177–91PubMedCrossRef
38.
go back to reference Vickers K, McNally RJ. Is premenstrual dysphoria a variant of panic disorder: a review. Clin Psychol Rev 2004 Dec; 24(8): 933–56PubMed Vickers K, McNally RJ. Is premenstrual dysphoria a variant of panic disorder: a review. Clin Psychol Rev 2004 Dec; 24(8): 933–56PubMed
39.
go back to reference Perugi G, Akiskal HS, Ramacciotti S, et al. Depressive comorbidity of panic, social phobic, and obsessive-compulsive disorders re-examined: is there a bipolar II connection? J Psychiatr Res 1999 Jan–Feb; 33(1): 53–61PubMedCrossRef Perugi G, Akiskal HS, Ramacciotti S, et al. Depressive comorbidity of panic, social phobic, and obsessive-compulsive disorders re-examined: is there a bipolar II connection? J Psychiatr Res 1999 Jan–Feb; 33(1): 53–61PubMedCrossRef
40.
go back to reference Kessler RC, Stang PE, Wittchen HU, et al. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry 1998 Sep; 55(9): 801–8PubMedCrossRef Kessler RC, Stang PE, Wittchen HU, et al. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry 1998 Sep; 55(9): 801–8PubMedCrossRef
41.
go back to reference Otto MW, Pollack MH, Sachs GS, et al. Alcohol dependence in panic disorder patients. J Psychiatr Res 1992 Jan; 26(1): 29–38PubMedCrossRef Otto MW, Pollack MH, Sachs GS, et al. Alcohol dependence in panic disorder patients. J Psychiatr Res 1992 Jan; 26(1): 29–38PubMedCrossRef
42.
go back to reference Chignon JM, Lepine JP, Ades J. Panic disorder and alcoholism. Encephale 1991 Nov–Dec; 17(6): 519–23PubMed Chignon JM, Lepine JP, Ades J. Panic disorder and alcoholism. Encephale 1991 Nov–Dec; 17(6): 519–23PubMed
43.
go back to reference Lepola U, Koponen H, Leinonen E. A naturalistic 6-year follow-up study of patients with panic disorder. Acta Psychiatr Scand 1996 Mar; 93(3): 181–3PubMedCrossRef Lepola U, Koponen H, Leinonen E. A naturalistic 6-year follow-up study of patients with panic disorder. Acta Psychiatr Scand 1996 Mar; 93(3): 181–3PubMedCrossRef
44.
go back to reference Cox BJ, Norton GR, Swinson RP, et al. Substance abuse and panic-related anxiety: a critical review. Behav Res Ther 1990; 28(5): 385–93PubMedCrossRef Cox BJ, Norton GR, Swinson RP, et al. Substance abuse and panic-related anxiety: a critical review. Behav Res Ther 1990; 28(5): 385–93PubMedCrossRef
45.
go back to reference Brown TA, Campbell LA, Lehman CL, et al. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J Abnorm Psychol 2001; 11: 585–99CrossRef Brown TA, Campbell LA, Lehman CL, et al. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J Abnorm Psychol 2001; 11: 585–99CrossRef
46.
go back to reference Breier A, Charney DS, Heninger GR. Agoraphobia with panic attacks: development, diagnostic stability and course of illness. Arch Gen Psychiatry 1986; 43: 1029–36PubMedCrossRef Breier A, Charney DS, Heninger GR. Agoraphobia with panic attacks: development, diagnostic stability and course of illness. Arch Gen Psychiatry 1986; 43: 1029–36PubMedCrossRef
47.
go back to reference Faravelli C, Albanesi G. Agoraphobia with panic attacks: one year prospective follow-up. Compr Psychiatry 1987; 28: 481–7PubMedCrossRef Faravelli C, Albanesi G. Agoraphobia with panic attacks: one year prospective follow-up. Compr Psychiatry 1987; 28: 481–7PubMedCrossRef
48.
go back to reference Keller MB, Yonkers KA, Warshaw MG, et al. Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up. J Nerv Ment Dis 1994; 182: 290–6PubMedCrossRef Keller MB, Yonkers KA, Warshaw MG, et al. Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up. J Nerv Ment Dis 1994; 182: 290–6PubMedCrossRef
49.
go back to reference Lelliott PT, Marks IM, Montera WO, et al. Agoraphobics 5 years after imipramine and exposure: outcome and predictors. J Nerv Ment Dis 1987; 175: 599–605PubMedCrossRef Lelliott PT, Marks IM, Montera WO, et al. Agoraphobics 5 years after imipramine and exposure: outcome and predictors. J Nerv Ment Dis 1987; 175: 599–605PubMedCrossRef
50.
go back to reference Lesser IM, Rubin RT, Pecknold SC, et al. Secondary depression in panic disorder and agoraphobia: frequency, severity and response to treatment. Arch Gen Psychiatry 1988; 45: 437–43PubMedCrossRef Lesser IM, Rubin RT, Pecknold SC, et al. Secondary depression in panic disorder and agoraphobia: frequency, severity and response to treatment. Arch Gen Psychiatry 1988; 45: 437–43PubMedCrossRef
51.
go back to reference Maier W, Buller R. One-year follow-up of panic disorder. Eur Arch Psychiatr Neurol Sci 1988; 238: 105–9 Maier W, Buller R. One-year follow-up of panic disorder. Eur Arch Psychiatr Neurol Sci 1988; 238: 105–9
52.
go back to reference Noyes Jr R, Clancy J, Woodsman C, et al. Environmental factors related to the outcome of panic disorder: a seven-year follow-up study. J Nerv Ment Dis 1993; 181: 529–33PubMedCrossRef Noyes Jr R, Clancy J, Woodsman C, et al. Environmental factors related to the outcome of panic disorder: a seven-year follow-up study. J Nerv Ment Dis 1993; 181: 529–33PubMedCrossRef
53.
go back to reference Scheibe G, Albus M. Predictors of outcome in panic disorder: a 5-year prospective follow up study. J Affect Disorder 1996; 41: 111–6CrossRef Scheibe G, Albus M. Predictors of outcome in panic disorder: a 5-year prospective follow up study. J Affect Disorder 1996; 41: 111–6CrossRef
54.
go back to reference Wittchen H-U. Natural course and spontaneous remissions of untreated anxiety disorders: results of the Munich follow-up study. In: Hand I, Wittchen H-U, editors. Panic and phobias 2. Berlin; Sperlag, 1988: 3–17CrossRef Wittchen H-U. Natural course and spontaneous remissions of untreated anxiety disorders: results of the Munich follow-up study. In: Hand I, Wittchen H-U, editors. Panic and phobias 2. Berlin; Sperlag, 1988: 3–17CrossRef
55.
go back to reference Mavissakalian M, Hamann MS. DSM-III personality disorder in agoraphobia: II. Changes with treatment. Compr Psychiatry 1987; 28: 356–61 Mavissakalian M, Hamann MS. DSM-III personality disorder in agoraphobia: II. Changes with treatment. Compr Psychiatry 1987; 28: 356–61
56.
go back to reference Noyes R, Reich J, Christiansen J, et al. Outcome of panic disorder: relationship to diagnostic subtypes and comorbidity. Arch Gen Psychiatry 1990; 47: 809–18PubMedCrossRef Noyes R, Reich J, Christiansen J, et al. Outcome of panic disorder: relationship to diagnostic subtypes and comorbidity. Arch Gen Psychiatry 1990; 47: 809–18PubMedCrossRef
57.
go back to reference O’Rourke D, Fahy TJ, Brophy J, et al. The Galway Study of panic disorder III: outcome at 5 to 6 years. Br J Psychiatry 1996; 168: 462–9PubMedCrossRef O’Rourke D, Fahy TJ, Brophy J, et al. The Galway Study of panic disorder III: outcome at 5 to 6 years. Br J Psychiatry 1996; 168: 462–9PubMedCrossRef
58.
go back to reference Reich JH. DSM-III personality disorders and the outcome of treated panic disorder. Arch Gen Psychiatry 1988; 145: 1149–52 Reich JH. DSM-III personality disorders and the outcome of treated panic disorder. Arch Gen Psychiatry 1988; 145: 1149–52
59.
go back to reference Pollack MH, Otto MW, Rosenbaum J, et al. Longitudinal course of panic disorder: finding from the Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry 1990; 51: 12–6PubMed Pollack MH, Otto MW, Rosenbaum J, et al. Longitudinal course of panic disorder: finding from the Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry 1990; 51: 12–6PubMed
60.
go back to reference Simon GE, VonKorff M. Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area Study. Am J Psychiatry 1991 Nov; 148(11): 1494–500PubMed Simon GE, VonKorff M. Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area Study. Am J Psychiatry 1991 Nov; 148(11): 1494–500PubMed
61.
go back to reference Lin EH, Katon W, Von Korff M, et al. Frustrating patients: physician and patient perspectives among distressed high users of medical services. J Gen Intern Med 1991 May–Jun; 6(3): 241–6PubMedCrossRef Lin EH, Katon W, Von Korff M, et al. Frustrating patients: physician and patient perspectives among distressed high users of medical services. J Gen Intern Med 1991 May–Jun; 6(3): 241–6PubMedCrossRef
62.
go back to reference Kane Jr FJ, Harper RG, Wittels E. Angina as a symptom of psychiatric illness. South Med J 1988 Nov; 81(11): 1412–6PubMedCrossRef Kane Jr FJ, Harper RG, Wittels E. Angina as a symptom of psychiatric illness. South Med J 1988 Nov; 81(11): 1412–6PubMedCrossRef
63.
go back to reference Wulsin LR, Arnold LM, Hillard JR. Axis I disorders in ER patients with atypical chest pain. Int J Psychiatry Med 1991; 21(1): 37–46PubMedCrossRef Wulsin LR, Arnold LM, Hillard JR. Axis I disorders in ER patients with atypical chest pain. Int J Psychiatry Med 1991; 21(1): 37–46PubMedCrossRef
64.
go back to reference Logue MB, Thomas AM, Barbee JG, et al. Generalized anxiety disorder patients seek evaluation for cardiological symptoms at the same frequency as patients with panic disorder. J Psychiatr Res 1993 Jan–Mar; 27(1): 55–9PubMedCrossRef Logue MB, Thomas AM, Barbee JG, et al. Generalized anxiety disorder patients seek evaluation for cardiological symptoms at the same frequency as patients with panic disorder. J Psychiatr Res 1993 Jan–Mar; 27(1): 55–9PubMedCrossRef
65.
go back to reference Walker EA, Roy-Byrne PP, Katon WJ. Irritable bowel syndrome and psychiatric illness. Am J Psychiatry 1990; 147: 565–72PubMed Walker EA, Roy-Byrne PP, Katon WJ. Irritable bowel syndrome and psychiatric illness. Am J Psychiatry 1990; 147: 565–72PubMed
66.
go back to reference Lydiard RB, Fossey MD, Marsh W, et al. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosmoatics 1993; 34: 229–34CrossRef Lydiard RB, Fossey MD, Marsh W, et al. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosmoatics 1993; 34: 229–34CrossRef
67.
go back to reference Simon GE. Psychiatric disorder and functional somatic symptoms as predictors of health care use. Psychiatr Med. 1992; 10(3): 49–59PubMed Simon GE. Psychiatric disorder and functional somatic symptoms as predictors of health care use. Psychiatr Med. 1992; 10(3): 49–59PubMed
68.
go back to reference Katerndahl DA, Realini JP. Use of health care services by persons with panic symptoms. Psychiatr Serv 1997 Aug; 48(8): 1027–32PubMed Katerndahl DA, Realini JP. Use of health care services by persons with panic symptoms. Psychiatr Serv 1997 Aug; 48(8): 1027–32PubMed
69.
go back to reference Katon W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 1990 Nov; 12(6): 355–62PubMedCrossRef Katon W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 1990 Nov; 12(6): 355–62PubMedCrossRef
70.
go back to reference Simpson RJ, Kazmierczak T, Power KG, et al. Controlled comparison of the characteristics of patients with panic disorder. Br J Gen Pract 1994; 44: 352–6PubMed Simpson RJ, Kazmierczak T, Power KG, et al. Controlled comparison of the characteristics of patients with panic disorder. Br J Gen Pract 1994; 44: 352–6PubMed
71.
go back to reference Roy-Byrne PP, Stein MB, Russo J, et al. Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. J Clin Psychiatry 1999 Jul; 60(7): 492–9PubMedCrossRef Roy-Byrne PP, Stein MB, Russo J, et al. Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. J Clin Psychiatry 1999 Jul; 60(7): 492–9PubMedCrossRef
72.
go back to reference Ormel J, Koeter MW, Van Der Brink W, et al. Recognition, management, and course of anxiety and depression in clinical practice. Arch Gen Psychiatry 1991; 48: 700–6PubMedCrossRef Ormel J, Koeter MW, Van Der Brink W, et al. Recognition, management, and course of anxiety and depression in clinical practice. Arch Gen Psychiatry 1991; 48: 700–6PubMedCrossRef
73.
go back to reference Young AS, Klap R, Sherbourne CD, et al. The quality of care for depression and anxiety disorders in the United States. Arch Gen Psychiatry 2001; 58: 55–61PubMedCrossRef Young AS, Klap R, Sherbourne CD, et al. The quality of care for depression and anxiety disorders in the United States. Arch Gen Psychiatry 2001; 58: 55–61PubMedCrossRef
74.
go back to reference Roy-Byrne P, Katon W, Cowley D, et al. A randomised effect trail of collaborative care for patients with panic disorder in the primary care. Arch Gen Psychiatry 2001; 58: 869–76PubMedCrossRef Roy-Byrne P, Katon W, Cowley D, et al. A randomised effect trail of collaborative care for patients with panic disorder in the primary care. Arch Gen Psychiatry 2001; 58: 869–76PubMedCrossRef
75.
go back to reference Roy-Byrne P, Wagner AW, Scraunfnagel BS. Understanding and treating panic disorder in the primary care setting. J Clin Psychiatry 2005; 66Suppl. 4: 16–22PubMed Roy-Byrne P, Wagner AW, Scraunfnagel BS. Understanding and treating panic disorder in the primary care setting. J Clin Psychiatry 2005; 66Suppl. 4: 16–22PubMed
76.
go back to reference Culpepper L. Identifying and treating panic disorder in primary care. J Clin Psychiatry 2004; 65Suppl. 5: 19–23PubMed Culpepper L. Identifying and treating panic disorder in primary care. J Clin Psychiatry 2004; 65Suppl. 5: 19–23PubMed
77.
go back to reference Mojtabai R, Olfson M, Mechanic D. Perceived need and help-seeking in adults with mood, anxiety, or substance use disorders. Arch Gen Psychiatry 2002 Jan; 59(1): 77–84PubMedCrossRef Mojtabai R, Olfson M, Mechanic D. Perceived need and help-seeking in adults with mood, anxiety, or substance use disorders. Arch Gen Psychiatry 2002 Jan; 59(1): 77–84PubMedCrossRef
78.
go back to reference Roy-Byrne P, Cowley DS. Clinical approach to treatment-resistant panic disorder. In: Rosenbaum JF, Pollack MH, editors. Panic disorder and its treatment. New York: Marcel Dekker, 1998: 205–26 Roy-Byrne P, Cowley DS. Clinical approach to treatment-resistant panic disorder. In: Rosenbaum JF, Pollack MH, editors. Panic disorder and its treatment. New York: Marcel Dekker, 1998: 205–26
79.
go back to reference Grilo CM, Money R, Barlow DH, et al. Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder. Compr Psychiatry 1998 Nov–Dec; 39(6): 323–32PubMedCrossRef Grilo CM, Money R, Barlow DH, et al. Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder. Compr Psychiatry 1998 Nov–Dec; 39(6): 323–32PubMedCrossRef
80.
go back to reference Roy-Byrne PP, Craske MG, Stein MB, et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry 2005 Mar; 62(3): 290–8PubMedCrossRef Roy-Byrne PP, Craske MG, Stein MB, et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry 2005 Mar; 62(3): 290–8PubMedCrossRef
81.
go back to reference Roy-Byrne PP, Russo J, Cowley DS, et al. Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. J Clin Psychiatry 2003 Apr; 64(4): 383–9PubMedCrossRef Roy-Byrne PP, Russo J, Cowley DS, et al. Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. J Clin Psychiatry 2003 Apr; 64(4): 383–9PubMedCrossRef
82.
go back to reference Broocks A, Bandelow B, Pekrun G, et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 1998 May; 155(5): 603–9PubMed Broocks A, Bandelow B, Pekrun G, et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 1998 May; 155(5): 603–9PubMed
83.
go back to reference Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev 1995; 15: 819–44CrossRef Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev 1995; 15: 819–44CrossRef
84.
go back to reference Clum GA, Clum GA, Suris R. A meta-analysis of treatments for panic disorder. J Consult Clin Psychol 1993; 61: 317–26PubMedCrossRef Clum GA, Clum GA, Suris R. A meta-analysis of treatments for panic disorder. J Consult Clin Psychol 1993; 61: 317–26PubMedCrossRef
85.
go back to reference Klein DF. Flawed meta-analyses compared psychotherapy with pharmacotherapy. Am J Psychiatry 2000; 157: 1204–11PubMedCrossRef Klein DF. Flawed meta-analyses compared psychotherapy with pharmacotherapy. Am J Psychiatry 2000; 157: 1204–11PubMedCrossRef
86.
go back to reference Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005; 88: 27–45PubMedCrossRef Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005; 88: 27–45PubMedCrossRef
87.
go back to reference Furukawa TA, Watanabe N. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia. Br J Psychiatry 2006; 188: 305–12PubMedCrossRef Furukawa TA, Watanabe N. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia. Br J Psychiatry 2006; 188: 305–12PubMedCrossRef
88.
go back to reference Noyes R, Clancey J, Coryell WH, et al. A withdrawal syndrome after abrupt discontinuation of alprazolam. Am J Psychiatry 1985; 142: 114–6PubMed Noyes R, Clancey J, Coryell WH, et al. A withdrawal syndrome after abrupt discontinuation of alprazolam. Am J Psychiatry 1985; 142: 114–6PubMed
89.
go back to reference Pecknold JC, Swinson RP, Kuch K, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial (III): discontinuation effects. Arch Gen Psychiatry 1988; 45: 429–36PubMedCrossRef Pecknold JC, Swinson RP, Kuch K, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial (III): discontinuation effects. Arch Gen Psychiatry 1988; 45: 429–36PubMedCrossRef
90.
go back to reference Ballenger JC. Long-term pharmacologic treatment of panic disorder. J Clin Psychiatry 1991; 52: 18–23PubMed Ballenger JC. Long-term pharmacologic treatment of panic disorder. J Clin Psychiatry 1991; 52: 18–23PubMed
91.
go back to reference Ballenger JC. Medication discontinuation in panic disorder. J Clin Psychiatry 1992; 53: 26–31PubMed Ballenger JC. Medication discontinuation in panic disorder. J Clin Psychiatry 1992; 53: 26–31PubMed
92.
go back to reference Pecknold JC. Discontinuation reactions to alprazolam in panic disorder. J Psychiatr Res 1993; 27: 155–70PubMedCrossRef Pecknold JC. Discontinuation reactions to alprazolam in panic disorder. J Psychiatr Res 1993; 27: 155–70PubMedCrossRef
93.
go back to reference Western D, Morrison K. A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically-supported therapies. J Consult Clin Psychol 2001; 69: 875–99CrossRef Western D, Morrison K. A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically-supported therapies. J Consult Clin Psychol 2001; 69: 875–99CrossRef
94.
go back to reference Shear MK, Houck P, Greeno C, et al. Emotion-focused psychotherapy for patients with panic disorder. Am J Psychiatry 2001; 158(12): 1993–8PubMedCrossRef Shear MK, Houck P, Greeno C, et al. Emotion-focused psychotherapy for patients with panic disorder. Am J Psychiatry 2001; 158(12): 1993–8PubMedCrossRef
95.
go back to reference Hofmann SG, Barlow DH, Papp LA, et al. Pretreatment attrition in comparative treatment outcome study on panic disorder. Am J Psychiatry 1998; 155: 45–7 Hofmann SG, Barlow DH, Papp LA, et al. Pretreatment attrition in comparative treatment outcome study on panic disorder. Am J Psychiatry 1998; 155: 45–7
96.
go back to reference Otto MW, Tuby KS, Gould RA, et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001; 158: 1989–92PubMedCrossRef Otto MW, Tuby KS, Gould RA, et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001; 158: 1989–92PubMedCrossRef
97.
go back to reference Stuart GL, Treat TA, Wade WA. Effectiveness of an empirically-based treatment for panic disorder delivered in a service clinic setting: 1-year follow-up. J Consult Clin Psychol 2000; 68: 506–12PubMedCrossRef Stuart GL, Treat TA, Wade WA. Effectiveness of an empirically-based treatment for panic disorder delivered in a service clinic setting: 1-year follow-up. J Consult Clin Psychol 2000; 68: 506–12PubMedCrossRef
98.
go back to reference Beck AT, Sokol L, Clark DA, et al. A cross-over study of focused cognitive therapy for panic disorder. Am J Psychiatry 1992; 149: 778–83PubMed Beck AT, Sokol L, Clark DA, et al. A cross-over study of focused cognitive therapy for panic disorder. Am J Psychiatry 1992; 149: 778–83PubMed
99.
go back to reference Burns EL, Thorpe GJ, Cavallaro LA. Agoraphobia 8 years after behavioral treatment: a follow-up study with interview, self-report, and behavioral data. Behav Ther 1986; 17: 580–91CrossRef Burns EL, Thorpe GJ, Cavallaro LA. Agoraphobia 8 years after behavioral treatment: a follow-up study with interview, self-report, and behavioral data. Behav Ther 1986; 17: 580–91CrossRef
100.
go back to reference Emmelkamp PMG, Kuipers ACM. Agoraphobia: a follow-up study four years after treatment. Br J Psychiatry 1979; 134: 352–5PubMedCrossRef Emmelkamp PMG, Kuipers ACM. Agoraphobia: a follow-up study four years after treatment. Br J Psychiatry 1979; 134: 352–5PubMedCrossRef
101.
go back to reference Fava G, Zielezny M, Savron G, et al. Long term effects of behavioral treatment for panic disorder with agoraphobia. Br J Psychiatry 1995; 166: 87–92PubMedCrossRef Fava G, Zielezny M, Savron G, et al. Long term effects of behavioral treatment for panic disorder with agoraphobia. Br J Psychiatry 1995; 166: 87–92PubMedCrossRef
102.
go back to reference Hafner RJ. Fresh symptom emergence after intensive behaviour therapy. Br J Psychiatry 1976; 129: 378–83PubMedCrossRef Hafner RJ. Fresh symptom emergence after intensive behaviour therapy. Br J Psychiatry 1976; 129: 378–83PubMedCrossRef
103.
go back to reference Marks I. Phobic disorders four years after treatment: a prospective follow-up. Br J Psychiatry 1971; 118: 683–8PubMedCrossRef Marks I. Phobic disorders four years after treatment: a prospective follow-up. Br J Psychiatry 1971; 118: 683–8PubMedCrossRef
104.
go back to reference Munby M, Johnston DW. Agoraphobia: the long-term follow-up of behavioural treatment. Br J Psychiatry 1980; 137: 418–27PubMedCrossRef Munby M, Johnston DW. Agoraphobia: the long-term follow-up of behavioural treatment. Br J Psychiatry 1980; 137: 418–27PubMedCrossRef
105.
go back to reference Nagy LM, Krystal JH, Charney DS. Long term outcome of panic disorder after short-term imipramine and behavioral group treatment. J Clin Psychopharmacology 1993; 13: 16–24 Nagy LM, Krystal JH, Charney DS. Long term outcome of panic disorder after short-term imipramine and behavioral group treatment. J Clin Psychopharmacology 1993; 13: 16–24
106.
go back to reference Goldberg C. Cognitive-behavioral therapy for panic: effectiveness and limitations. Psychiatr Q 1998; 69(1): 23–44PubMedCrossRef Goldberg C. Cognitive-behavioral therapy for panic: effectiveness and limitations. Psychiatr Q 1998; 69(1): 23–44PubMedCrossRef
107.
go back to reference O’Sullivan G, Marks IM. Long-term outcome of phobic and obessive-compulsive disorders after treatment. In: Noyes R, Burrows GD, Roth M, editors. Handbook of anxiety. Vol. 4. Amsterdam: Elsevier, 1990: 87–108 O’Sullivan G, Marks IM. Long-term outcome of phobic and obessive-compulsive disorders after treatment. In: Noyes R, Burrows GD, Roth M, editors. Handbook of anxiety. Vol. 4. Amsterdam: Elsevier, 1990: 87–108
108.
go back to reference Otto MW. Integrated treatment of panic disorder. J Clin Psychiatry 1997; 58: 36–42CrossRef Otto MW. Integrated treatment of panic disorder. J Clin Psychiatry 1997; 58: 36–42CrossRef
109.
go back to reference Van Balkom AJ, Bakker A, Spinhoven P, et al. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 1997; 185(8): 510–6PubMedCrossRef Van Balkom AJ, Bakker A, Spinhoven P, et al. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 1997; 185(8): 510–6PubMedCrossRef
110.
go back to reference Curtis GC, Massana J, Udina C, et al. Maintenance drug therapy of panic disorder. J Psychiatr Res 1993; 27Suppl. 1: 127–42PubMedCrossRef Curtis GC, Massana J, Udina C, et al. Maintenance drug therapy of panic disorder. J Psychiatr Res 1993; 27Suppl. 1: 127–42PubMedCrossRef
111.
go back to reference Brown TA, Barlow DH. Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for treatment. J Consult Clin Psychol 1995; 63: 754–65PubMedCrossRef Brown TA, Barlow DH. Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for treatment. J Consult Clin Psychol 1995; 63: 754–65PubMedCrossRef
112.
go back to reference Goisman RM, Warshaw MG, Keller MB. Psychosocial treatment prescriptions for generalized anxiety disorder, panic disorder, and social phobia, 1991–1996. Am J Psychiatry 1999; 156(11): 1819–21PubMed Goisman RM, Warshaw MG, Keller MB. Psychosocial treatment prescriptions for generalized anxiety disorder, panic disorder, and social phobia, 1991–1996. Am J Psychiatry 1999; 156(11): 1819–21PubMed
113.
go back to reference Toni C, Perugi G, Frare F, et al. Spontaneous treatment discontinuation in panic disorder patients treated with antidepressants. Acta Psychiatr Scand 2004 Aug; 110(2): 130–7PubMedCrossRef Toni C, Perugi G, Frare F, et al. Spontaneous treatment discontinuation in panic disorder patients treated with antidepressants. Acta Psychiatr Scand 2004 Aug; 110(2): 130–7PubMedCrossRef
114.
go back to reference Kumar S, Oakley-Browne M. Panic disorder. Clin Evid 2003 Dec; 10: 1188–95PubMed Kumar S, Oakley-Browne M. Panic disorder. Clin Evid 2003 Dec; 10: 1188–95PubMed
115.
go back to reference Otto MW, Tuby KS, Gould RA. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001 Dec; 158(12): 1989–92PubMedCrossRef Otto MW, Tuby KS, Gould RA. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001 Dec; 158(12): 1989–92PubMedCrossRef
116.
go back to reference Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand 2002 Sep; 106(3): 163–7PubMedCrossRef Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand 2002 Sep; 106(3): 163–7PubMedCrossRef
117.
go back to reference Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995 Mar; 10(1): 45–9PubMedCrossRef Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995 Mar; 10(1): 45–9PubMedCrossRef
118.
go back to reference Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fěxed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36–42PubMed Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fěxed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36–42PubMed
119.
go back to reference Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167: 374–9PubMedCrossRef Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167: 374–9PubMedCrossRef
120.
go back to reference Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. The Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95: 153–60 Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. The Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95: 153–60
121.
go back to reference Bakker A, van Dyck R, Spjnhoven P, et al. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry 1999; 60: 831–8PubMedCrossRef Bakker A, van Dyck R, Spjnhoven P, et al. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry 1999; 60: 831–8PubMedCrossRef
122.
go back to reference Judge R, Steiner M. The long-term efficacy of paroxetine in panic disorder [abstract]. Eur Neuropsychopharmacol 1996; 6: 207CrossRef Judge R, Steiner M. The long-term efficacy of paroxetine in panic disorder [abstract]. Eur Neuropsychopharmacol 1996; 6: 207CrossRef
123.
go back to reference Gorman J, Wolkow R. Sertraline as a treatment for panic disorder. Neuropsychopharrnacology 1994; 10: 117–75 Gorman J, Wolkow R. Sertraline as a treatment for panic disorder. Neuropsychopharrnacology 1994; 10: 117–75
124.
go back to reference DuBoff E, England D, Ferguson JM. Double-blind comparison in three fixed doses of sertraline and placebo in patients with panic disorder [abstract]. Eur Neuropsychopharmacol 1995; 5: 287CrossRef DuBoff E, England D, Ferguson JM. Double-blind comparison in three fixed doses of sertraline and placebo in patients with panic disorder [abstract]. Eur Neuropsychopharmacol 1995; 5: 287CrossRef
125.
go back to reference Wolkow R, Apter J, Clayton A. Double-blind flexible-dose study of sertraline and placebo in patients with panic disorder. Eur Neuropsychopharmacol 1996; 6: 113–9CrossRef Wolkow R, Apter J, Clayton A. Double-blind flexible-dose study of sertraline and placebo in patients with panic disorder. Eur Neuropsychopharmacol 1996; 6: 113–9CrossRef
126.
go back to reference Londborg PD, Wolkow R, Smith WT, et al. Sertraline in the treatment of panic disorder. Br J Psychiatry 1998; 73: 54–60CrossRef Londborg PD, Wolkow R, Smith WT, et al. Sertraline in the treatment of panic disorder. Br J Psychiatry 1998; 73: 54–60CrossRef
127.
go back to reference Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder. a double-blind multicenter trial. Am J Psychiatry 1998; 155: 1189–95 Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder. a double-blind multicenter trial. Am J Psychiatry 1998; 155: 1189–95
128.
go back to reference Rapoport MH, Wolkow RM, Rubin A, et al. Sertraline treatment of panic disorder: results of a long term study. Acta Psychiatr Scand 2001; 104: 289–98CrossRef Rapoport MH, Wolkow RM, Rubin A, et al. Sertraline treatment of panic disorder: results of a long term study. Acta Psychiatr Scand 2001; 104: 289–98CrossRef
129.
go back to reference Wade AG, Lepola U, Koponen J, et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170: 549–53PubMedCrossRef Wade AG, Lepola U, Koponen J, et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170: 549–53PubMedCrossRef
130.
go back to reference Lepola UM, Wade AG, Leinoncn EV, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998; 59: 528–34PubMedCrossRef Lepola UM, Wade AG, Leinoncn EV, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998; 59: 528–34PubMedCrossRef
131.
go back to reference Leinonen E, Lepola U, Koponen H, et al. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 2000; 25: 24–32PubMed Leinonen E, Lepola U, Koponen H, et al. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 2000; 25: 24–32PubMed
132.
go back to reference Perna G, Bertani A, Caldirola D, et al. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2001 May; 34(3): 85–90PubMedCrossRef Perna G, Bertani A, Caldirola D, et al. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2001 May; 34(3): 85–90PubMedCrossRef
133.
go back to reference Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003 Nov; 64(11): 1322–7PubMedCrossRef Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003 Nov; 64(11): 1322–7PubMedCrossRef
134.
go back to reference den Boer JA, Westenberg HG. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 1990; 102: 85–94CrossRef den Boer JA, Westenberg HG. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 1990; 102: 85–94CrossRef
135.
go back to reference Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993; 544: 146–9 Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993; 544: 146–9
136.
go back to reference Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993; 13: 321–6PubMedCrossRef Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993; 13: 321–6PubMedCrossRef
137.
go back to reference Nair NPV, Bakish D, Saxena B, et al. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety 1996; 2: 192–8PubMedCrossRef Nair NPV, Bakish D, Saxena B, et al. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety 1996; 2: 192–8PubMedCrossRef
138.
go back to reference Gorman JM, Liebowitz MR, Fyer AJ, et al. An open trial of fluoxetine in the treatment of panic attacks [published erratum appears in J Clin Psychopharmacol 1988 Feb; 8(1): 13]. J Clin Psychopharmacol 1987; 7: 329–32PubMedCrossRef Gorman JM, Liebowitz MR, Fyer AJ, et al. An open trial of fluoxetine in the treatment of panic attacks [published erratum appears in J Clin Psychopharmacol 1988 Feb; 8(1): 13]. J Clin Psychopharmacol 1987; 7: 329–32PubMedCrossRef
139.
go back to reference Pecknold JC, Luthe L, Iny L, et al. Fluoxetine in panic disorder. pharmacologic and tritiated platelet imipramine and paroxetine binding study. J Psychiatry Neurosci 1995; 2: 193–8 Pecknold JC, Luthe L, Iny L, et al. Fluoxetine in panic disorder. pharmacologic and tritiated platelet imipramine and paroxetine binding study. J Psychiatry Neurosci 1995; 2: 193–8
140.
go back to reference Schneier FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990; 10: 119–21PubMedCrossRef Schneier FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990; 10: 119–21PubMedCrossRef
141.
go back to reference Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 1998; 155: 1570–7 Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 1998; 155: 1570–7
142.
go back to reference Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 352–9PubMedCrossRef Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 352–9PubMedCrossRef
143.
go back to reference Cohen SD, Monteiro W, Marks IM. Two-year follow-up of agoraphobics after exposure and imipramine. Br J Psychiatry 1984; 144: 276–81PubMedCrossRef Cohen SD, Monteiro W, Marks IM. Two-year follow-up of agoraphobics after exposure and imipramine. Br J Psychiatry 1984; 144: 276–81PubMedCrossRef
144.
go back to reference Mavissakalian M, Michelson L. Two-year follow-up of exposure and imipramine treatment of agoraphobia. Am J Psychiatry 1986; 143: 1106–12PubMed Mavissakalian M, Michelson L. Two-year follow-up of exposure and imipramine treatment of agoraphobia. Am J Psychiatry 1986; 143: 1106–12PubMed
145.
go back to reference Noyes R, Garvey M, Cook B. Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Disord 1989; 16: 249–57PubMedCrossRef Noyes R, Garvey M, Cook B. Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Disord 1989; 16: 249–57PubMedCrossRef
146.
go back to reference Zitrin CM, Klein DF, Woemer MG. Treatment of agoraphobia with group exposure in vivo and imipramine. Arch Gen Psychiatry 1980; 37: 63–72PubMedCrossRef Zitrin CM, Klein DF, Woemer MG. Treatment of agoraphobia with group exposure in vivo and imipramine. Arch Gen Psychiatry 1980; 37: 63–72PubMedCrossRef
147.
go back to reference Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine and placebo. Cross-National Collaborative. Panic Study, second phase investigators. Br J Psychiatry 1992; 160: 191–202 Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine and placebo. Cross-National Collaborative. Panic Study, second phase investigators. Br J Psychiatry 1992; 160: 191–202
148.
go back to reference Uhlenhuth EH, Matuzas W, Glass RM, et al. Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989; 17: 261–70PubMedCrossRef Uhlenhuth EH, Matuzas W, Glass RM, et al. Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989; 17: 261–70PubMedCrossRef
149.
go back to reference Mavassakalian M, Perel J. Imipramine in the treatment of agoraphobia: dose response relationships. Am J Psychiatry 1985; 142: 1032–6 Mavassakalian M, Perel J. Imipramine in the treatment of agoraphobia: dose response relationships. Am J Psychiatry 1985; 142: 1032–6
150.
go back to reference Cassano GB, Toni C, Musetti L. Treatment of panic disorder. In: Biggio G, Concas A, Costa E, editors. GABAergic synaptic transmission. New York: Raven Press, 1992: 449–60 Cassano GB, Toni C, Musetti L. Treatment of panic disorder. In: Biggio G, Concas A, Costa E, editors. GABAergic synaptic transmission. New York: Raven Press, 1992: 449–60
151.
go back to reference Andersch S, Rosenberg NK, Kullingsjo H, et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder: a Scandinavian multicenter study. Acta Psychiatr Scand 1991; 365: 18–27CrossRef Andersch S, Rosenberg NK, Kullingsjo H, et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder: a Scandinavian multicenter study. Acta Psychiatr Scand 1991; 365: 18–27CrossRef
152.
go back to reference Mavissakalian MR, Perel JM. Imipramine dose-response relationship in panic disorder with agoraphobia. Arch Gen Psychiatry 1989; 46: 127–31PubMedCrossRef Mavissakalian MR, Perel JM. Imipramine dose-response relationship in panic disorder with agoraphobia. Arch Gen Psychiatry 1989; 46: 127–31PubMedCrossRef
153.
go back to reference Mavissakalian MR, Perel JM. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am J Psychiatry 1995; 152: 673–82PubMed Mavissakalian MR, Perel JM. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am J Psychiatry 1995; 152: 673–82PubMed
154.
go back to reference Maier W, Roth SM, Argyle N, et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder? Eur Arch Psychiatry Clin Neurosci 1991; 241: 151–8PubMedCrossRef Maier W, Roth SM, Argyle N, et al. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder? Eur Arch Psychiatry Clin Neurosci 1991; 241: 151–8PubMedCrossRef
155.
go back to reference Mellergard M, Lorentzen K, Bech P, et al. A trend analysis of changes during treatment of panic disorder with alprazolam and imipramine. Acta Psychiatr Scand Suppl 1991; 365: 28–32CrossRef Mellergard M, Lorentzen K, Bech P, et al. A trend analysis of changes during treatment of panic disorder with alprazolam and imipramine. Acta Psychiatr Scand Suppl 1991; 365: 28–32CrossRef
156.
go back to reference Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 251–61PubMedCrossRef Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 251–61PubMedCrossRef
157.
go back to reference Cassano GB, Petracca A, Perugi G, et al. Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine. J Affect Disord 1988; 14: 123–7 Cassano GB, Petracca A, Perugi G, et al. Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine. J Affect Disord 1988; 14: 123–7
158.
go back to reference McTavish D, Benfield P. Clomipramine: an overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 1990; 39(1): 136–53PubMedCrossRef McTavish D, Benfield P. Clomipramine: an overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 1990; 39(1): 136–53PubMedCrossRef
159.
go back to reference Sasson Y, Inacu I, Fux M, et al. A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 1999; 9(3): 191–6PubMedCrossRef Sasson Y, Inacu I, Fux M, et al. A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 1999; 9(3): 191–6PubMedCrossRef
160.
go back to reference Lydiard RB, Morton WA, Emmanuel NP, et al. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 1993; 29(2): 183–8PubMed Lydiard RB, Morton WA, Emmanuel NP, et al. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 1993; 29(2): 183–8PubMed
161.
go back to reference Kalus O, Asnis GM, Rubinson E, et al. Desipramine treatment in panic disorder. J Affect Disord 1991; 21(4): 239–44PubMedCrossRef Kalus O, Asnis GM, Rubinson E, et al. Desipramine treatment in panic disorder. J Affect Disord 1991; 21(4): 239–44PubMedCrossRef
162.
go back to reference Solyom L, Heseltine GFD, McClure DJ, et al. Interaction of phenelzine and exposure in phobias. Can Psychiatr J 1973; 18: 25–32 Solyom L, Heseltine GFD, McClure DJ, et al. Interaction of phenelzine and exposure in phobias. Can Psychiatr J 1973; 18: 25–32
163.
go back to reference Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacology 1973; 32: 237–54CrossRef Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacology 1973; 32: 237–54CrossRef
164.
go back to reference Tyrer T. Clinical effects of abrupt withdrawal from tricyclic antidepressants and monoamine oxidase inhibitors after long term treatment. J Affect Disord 1984; 6: 1–7PubMedCrossRef Tyrer T. Clinical effects of abrupt withdrawal from tricyclic antidepressants and monoamine oxidase inhibitors after long term treatment. J Affect Disord 1984; 6: 1–7PubMedCrossRef
165.
go back to reference Tiller JW, Bouwer C, Behnke K. Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 1999; 249Suppl. 1: S7–10PubMedCrossRef Tiller JW, Bouwer C, Behnke K. Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 1999; 249Suppl. 1: S7–10PubMedCrossRef
166.
go back to reference Krüger MB, Dahl AA. The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci 1999; 249Suppl. 1: S19–24PubMedCrossRef Krüger MB, Dahl AA. The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci 1999; 249Suppl. 1: S19–24PubMedCrossRef
167.
go back to reference Uhlenhuth EH, Warner TD, Matuzas W. Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. J Clin Psychopharmacol 2002; 22(3): 275–84PubMedCrossRef Uhlenhuth EH, Warner TD, Matuzas W. Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. J Clin Psychopharmacol 2002; 22(3): 275–84PubMedCrossRef
168.
go back to reference Loerch B, Graf-Morgenstern M, Hautzinger M, et al. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry 1999; 174: 205–12PubMedCrossRef Loerch B, Graf-Morgenstern M, Hautzinger M, et al. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry 1999; 174: 205–12PubMedCrossRef
169.
go back to reference Schweizer E, Patterson W, Rickels K, et al. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993; 150: 1210–5PubMed Schweizer E, Patterson W, Rickels K, et al. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993; 150: 1210–5PubMed
170.
go back to reference Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose response study of efficacy, safety, and discontinuance. The Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol 1997; 17: 390–400 Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose response study of efficacy, safety, and discontinuance. The Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol 1997; 17: 390–400
171.
go back to reference Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991; 52: 69–76PubMed Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991; 52: 69–76PubMed
172.
go back to reference Beauclair L, Fontaine R, Annable L, et al. Clonazepam in the treatment of panic-disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychiatry 1994; 14: 111–8 Beauclair L, Fontaine R, Annable L, et al. Clonazepam in the treatment of panic-disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychiatry 1994; 14: 111–8
173.
go back to reference Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998; 59Suppl. 8: 47–54PubMed Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998; 59Suppl. 8: 47–54PubMed
174.
go back to reference Coplan JD, Pine DS, Papp LA, et al. An algorithm-oriented treatment approach for panic disorder. Psychiatr Ann 1996; 264: 192–201 Coplan JD, Pine DS, Papp LA, et al. An algorithm-oriented treatment approach for panic disorder. Psychiatr Ann 1996; 264: 192–201
175.
go back to reference Noyes Jr R, Clancey J, Woodman C, et al. Environmental factors related to the outcome of panic disorder: a seven-year follow-up study. J Nerv Ment Disord 1993; 181: 529–38CrossRef Noyes Jr R, Clancey J, Woodman C, et al. Environmental factors related to the outcome of panic disorder: a seven-year follow-up study. J Nerv Ment Disord 1993; 181: 529–38CrossRef
176.
go back to reference Keller MB, Yonkers KA, Warshaw MG, et al. Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up. J Nerv Ment Disord 1993; 182: 290–6 Keller MB, Yonkers KA, Warshaw MG, et al. Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up. J Nerv Ment Disord 1993; 182: 290–6
177.
go back to reference Faravelli C, Paterniti S, Scarpato A. A 5-year prospective, naturalistic follow-up study of panic disorder. Compr Psychiatry 1995; 36: 271–7PubMedCrossRef Faravelli C, Paterniti S, Scarpato A. A 5-year prospective, naturalistic follow-up study of panic disorder. Compr Psychiatry 1995; 36: 271–7PubMedCrossRef
178.
go back to reference Fava GA, Manganelli L. Subclinical symptoms of panic disorder. Psychother Psychosom 1999; 68: 281–9PubMedCrossRef Fava GA, Manganelli L. Subclinical symptoms of panic disorder. Psychother Psychosom 1999; 68: 281–9PubMedCrossRef
179.
180.
go back to reference McKenzie LJ, Risch SC. Fibrocystic breast disease following treatment with SSRIs. Am J Psychiatry 1995; 1: 152–3 McKenzie LJ, Risch SC. Fibrocystic breast disease following treatment with SSRIs. Am J Psychiatry 1995; 1: 152–3
181.
go back to reference Holland RL. Fluvoxamine in panic disorder: after discontinuation? Neuropsychopharmacology 1994; 10: 102 Holland RL. Fluvoxamine in panic disorder: after discontinuation? Neuropsychopharmacology 1994; 10: 102
182.
go back to reference Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997; 58(7): 291–7PubMedCrossRef Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997; 58(7): 291–7PubMedCrossRef
183.
go back to reference Judge R, Parry MG, Quail D, et al. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002; 17(5): 217–25PubMedCrossRef Judge R, Parry MG, Quail D, et al. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002; 17(5): 217–25PubMedCrossRef
184.
go back to reference Munjack DJ, Crocker B, Cabe D, et al. Alprazolam, propranolol and placebo in the treatment of panic disorder and agoraphobia with panic attack. J Clin Psychopharmacol 1989; 9: 22–7PubMed Munjack DJ, Crocker B, Cabe D, et al. Alprazolam, propranolol and placebo in the treatment of panic disorder and agoraphobia with panic attack. J Clin Psychopharmacol 1989; 9: 22–7PubMed
185.
go back to reference Lydiard RB, Lesser IM, Ballenger JC, et al. A fixed-dose study of alprazolam 2mg, alprazolam 6mg and placebo in panic disorder. J Clin Psychopharmacol 1992; 12: 96–103PubMedCrossRef Lydiard RB, Lesser IM, Ballenger JC, et al. A fixed-dose study of alprazolam 2mg, alprazolam 6mg and placebo in panic disorder. J Clin Psychopharmacol 1992; 12: 96–103PubMedCrossRef
186.
go back to reference Pollack MH, Tesar GE, Rosenbaum JF, et al. Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. J Clin Psychopharmacol 1986; 6: 302–4PubMedCrossRef Pollack MH, Tesar GE, Rosenbaum JF, et al. Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. J Clin Psychopharmacol 1986; 6: 302–4PubMedCrossRef
187.
go back to reference Pollack MH, Otto MW, Tesar GE, et al. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993; 13: 257–63PubMedCrossRef Pollack MH, Otto MW, Tesar GE, et al. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993; 13: 257–63PubMedCrossRef
188.
go back to reference Schweizer E, Rickeis K, Weiss S, et al. Maintenance drug treatment or panic disorder: I. Results of a prospective, placebo-controlled, comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993; 50: 51–60PubMedCrossRef Schweizer E, Rickeis K, Weiss S, et al. Maintenance drug treatment or panic disorder: I. Results of a prospective, placebo-controlled, comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993; 50: 51–60PubMedCrossRef
189.
go back to reference Worthington III JJ, Pollack MH, Otto MW, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. Psychopharmacol Bull 1998; 34: 199–205PubMed Worthington III JJ, Pollack MH, Otto MW, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. Psychopharmacol Bull 1998; 34: 199–205PubMed
190.
go back to reference Noyes R, Garvey MJ, Cook BL, et al. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989; 50: 163–9PubMed Noyes R, Garvey MJ, Cook BL, et al. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989; 50: 163–9PubMed
191.
go back to reference Schweizer E, Pohl R, Balon R, et al. Lorazepam vs alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990; 23: 90–3PubMedCrossRef Schweizer E, Pohl R, Balon R, et al. Lorazepam vs alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990; 23: 90–3PubMedCrossRef
192.
go back to reference Charney DS, Woods SW. Benzodiazepine treatment of panic disorder. a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989; 50: 418–23 Charney DS, Woods SW. Benzodiazepine treatment of panic disorder. a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989; 50: 418–23
193.
go back to reference Noyes Jr R, Burrows GD, Reich JH, et al. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 1996; 57: 349–55PubMed Noyes Jr R, Burrows GD, Reich JH, et al. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 1996; 57: 349–55PubMed
194.
go back to reference Dunner DL, Ishiki D, Avery DH, et al. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986; 47: 458–60PubMed Dunner DL, Ishiki D, Avery DH, et al. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986; 47: 458–60PubMed
195.
go back to reference Pecknold J, Luthe L, Munjack D, et al. A double-blind, placebo-controlled, multicentre study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacology 1994; 14: 314–21CrossRef Pecknold J, Luthe L, Munjack D, et al. A double-blind, placebo-controlled, multicentre study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacology 1994; 14: 314–21CrossRef
196.
go back to reference Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352: 1331–6PubMedCrossRef Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352: 1331–6PubMedCrossRef
197.
go back to reference van Balkom AJ, Bakker A, Spinhoven P, et al. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 1997; 185(8): 510–6PubMedCrossRef van Balkom AJ, Bakker A, Spinhoven P, et al. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 1997; 185(8): 510–6PubMedCrossRef
198.
go back to reference Lydiard RB, Laraia MT, Ballenger JC, et al. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry 1987; 144: 644–65 Lydiard RB, Laraia MT, Ballenger JC, et al. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry 1987; 144: 644–65
199.
go back to reference Cohen LS, Rosenbaum JF. Clonazepam: new uses and potential problems. J Clin Psychiatry 1987; 48: 50–5PubMed Cohen LS, Rosenbaum JF. Clonazepam: new uses and potential problems. J Clin Psychiatry 1987; 48: 50–5PubMed
200.
go back to reference Pollack MH, Tesar GE, Rosenbaum JF, et al. Clonazepam in the treatment of panic disorder and agoraphobia: one year of follow-up. J Clin Psychopharmacol 1986; 6: 302–4PubMedCrossRef Pollack MH, Tesar GE, Rosenbaum JF, et al. Clonazepam in the treatment of panic disorder and agoraphobia: one year of follow-up. J Clin Psychopharmacol 1986; 6: 302–4PubMedCrossRef
201.
go back to reference Howell EF, Laraia MT, Ballenger JC, et al. Lorazepam treatment of panic disorder [presented at the new research session]. 140th Annual Meeting of the American Psychiatric Association; 1987 May 7–14; Chicago (IL) Howell EF, Laraia MT, Ballenger JC, et al. Lorazepam treatment of panic disorder [presented at the new research session]. 140th Annual Meeting of the American Psychiatric Association; 1987 May 7–14; Chicago (IL)
202.
go back to reference Fux M, Taub M, Zohar J. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. Acta Psychiatr Scand 1993; 88: 235–7PubMedCrossRef Fux M, Taub M, Zohar J. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. Acta Psychiatr Scand 1993; 88: 235–7PubMedCrossRef
203.
go back to reference Aronson TA. Treatment-emergent depression with antidepressants in panic disorder. Compr Psychiatry 1989; 1(2): 267–71CrossRef Aronson TA. Treatment-emergent depression with antidepressants in panic disorder. Compr Psychiatry 1989; 1(2): 267–71CrossRef
204.
go back to reference Hallfors DD, Saxe L. The dependence potential of short half-life benzodiazepines: a meta-analysis. Am J Public Health 1993; 83: 1300–1304PubMedCrossRef Hallfors DD, Saxe L. The dependence potential of short half-life benzodiazepines: a meta-analysis. Am J Public Health 1993; 83: 1300–1304PubMedCrossRef
205.
go back to reference Salzman C. Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. J Psychiatr Res 1993; 27: 97–110PubMedCrossRef Salzman C. Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. J Psychiatr Res 1993; 27: 97–110PubMedCrossRef
206.
go back to reference Goddard AW, Brouette T, Almai A, et al. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001; 58: 681–6PubMedCrossRef Goddard AW, Brouette T, Almai A, et al. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001; 58: 681–6PubMedCrossRef
207.
go back to reference Pollack MH, Simon NH, Worthington JJ, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003; 17: 276–82PubMedCrossRef Pollack MH, Simon NH, Worthington JJ, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003; 17: 276–82PubMedCrossRef
208.
go back to reference Mavissakalian MR, Perel JM. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol 2002; 22: 294–9PubMedCrossRef Mavissakalian MR, Perel JM. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol 2002; 22: 294–9PubMedCrossRef
209.
go back to reference Ballenger JC. Medication discontinuation in panic disorder. J Clin Psychiatry 1992; 53: 26–31PubMed Ballenger JC. Medication discontinuation in panic disorder. J Clin Psychiatry 1992; 53: 26–31PubMed
210.
go back to reference Pollack MH, Marzol PC. Panic: course, complications, and treatment of panic disorder. J Psychopharmacol 2000; 14(2 Suppl. 1): S25–30PubMed Pollack MH, Marzol PC. Panic: course, complications, and treatment of panic disorder. J Psychopharmacol 2000; 14(2 Suppl. 1): S25–30PubMed
211.
go back to reference O’Rourke D, Fahy TJ, Brophy J, et al. The Galway Study of panic disorder: III. Outcome at 5 to 6 years. Br J Psychiatry 1996; 168: 462–9 O’Rourke D, Fahy TJ, Brophy J, et al. The Galway Study of panic disorder: III. Outcome at 5 to 6 years. Br J Psychiatry 1996; 168: 462–9
212.
go back to reference Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 1998; 155: 1570–7 Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 1998; 155: 1570–7
213.
go back to reference Mavissakalian MR, Perel JM. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1992; 49: 318–23PubMed Mavissakalian MR, Perel JM. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1992; 49: 318–23PubMed
214.
go back to reference Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol 1998; 18Suppl. 2: S12–18CrossRef Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol 1998; 18Suppl. 2: S12–18CrossRef
215.
go back to reference Katon W, Vitaliano PP, Anderson K, et al. Panic disorder: residual symptoms after the acute attacks abate. Compr Psychiatry 1987; 28: 151–8PubMedCrossRef Katon W, Vitaliano PP, Anderson K, et al. Panic disorder: residual symptoms after the acute attacks abate. Compr Psychiatry 1987; 28: 151–8PubMedCrossRef
216.
go back to reference Fava GA, Rafanelli C, Ottolini F, et al. Psychological well-being and residual symptoms in remitted patients with panic disorder and agoraphobia. J Affect Disord 2001; 65: 185–90PubMedCrossRef Fava GA, Rafanelli C, Ottolini F, et al. Psychological well-being and residual symptoms in remitted patients with panic disorder and agoraphobia. J Affect Disord 2001; 65: 185–90PubMedCrossRef
217.
go back to reference Katschnig H, Amering M, Stolk JM, et al. Predictors of quality of life in a long-term follow-up study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull 1996; 32: 149–55PubMed Katschnig H, Amering M, Stolk JM, et al. Predictors of quality of life in a long-term follow-up study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull 1996; 32: 149–55PubMed
218.
go back to reference Mark IM, Swinson RP, Basoglu M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br J Psychiatry 1993; 62: 776–87CrossRef Mark IM, Swinson RP, Basoglu M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br J Psychiatry 1993; 62: 776–87CrossRef
219.
go back to reference Roy-Byrne PP, Craske MG, Stein MB, et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry 2005; 62(3): 290–8PubMedCrossRef Roy-Byrne PP, Craske MG, Stein MB, et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry 2005; 62(3): 290–8PubMedCrossRef
220.
go back to reference Bakker A, van Balkom AJ, Spinhoven P, et al. Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review. J Nerv Ment Dis 1998; 186: 414–9PubMedCrossRef Bakker A, van Balkom AJ, Spinhoven P, et al. Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review. J Nerv Ment Dis 1998; 186: 414–9PubMedCrossRef
221.
go back to reference Barlow DH, Gorman JM, Shear MK, et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000; 283: 2529–36PubMedCrossRef Barlow DH, Gorman JM, Shear MK, et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000; 283: 2529–36PubMedCrossRef
222.
go back to reference Otto MW, Deveney C. Cogntive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. J Clin Psychiatry 2005; 66Suppl. 4: 28–32PubMed Otto MW, Deveney C. Cogntive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. J Clin Psychiatry 2005; 66Suppl. 4: 28–32PubMed
Metadata
Title
Diagnosis and Treatment of Agoraphobia with Panic Disorder
Authors
Dr Giulio Perugi
Franco Frare
Cristina Toni
Publication date
01-09-2007
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 9/2007
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200721090-00004

Other articles of this Issue 9/2007

CNS Drugs 9/2007 Go to the issue

Therapy In Practice

Bipolar II Disorder